# Daniel J Deangelo

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 232 papers | 17,832 citations | 28736 57 h-index | 16186 128 g-index |
| 235 all docs | 235 docs citations | 235 times ranked | 18781 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood Advances, 2022, 6, 818-827. | 2.5 | 5 |
| 2 | Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood, 2022, 139, 1135-1146. | 0.6 | 39 |
| 3 | Orthopedic toxicities among adolescents and young adults treated in DFCI ALL Consortium Trials. Blood Advances, 2022, 6, 72-81. | 2.5 | 7 |
| 4 | Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clinical Cancer Research, 2022, 28, 870-881. | 3.2 | 32 |
| 5 | Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee. Journal of Hematology and Oncology, 2022, 15, 1. | 6.9 | 33 |
| 6 | Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy. Blood Advances, 2022, 6, 2835-2846. | 2.5 | 8 |
| 7 | Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leukemia and Lymphoma, 2022, 63, 1934-1941. | 0.6 | 13 |
| 8 | Orthopaedic adverse events among adolescents and adults treated with asparaginase for acute lymphoblastic leukaemia. British Journal of Haematology, 2022, 198, 421-430. | 1.2 | 1 |
| 9 | Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Experimental Hematology, 2022, 107, 14-19. | 0.2 | 10 |
| 10 | Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e836-e843. | 0.2 | 1 |
| 11 | Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Advances, 2022, 6, 5750-5762. | 2.5 | 20 |
| 12 | Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention. Journal of Clinical Oncology, 2022, 40, 3709-3718. | 0.8 | 9 |
| 13 | Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis. Leukemia, 2022, 36, 2108-2120. | 3.3 | 22 |
| 14 | Characterization of the Relationship of Inotuzumab Ozogamicin Exposure With Efficacy and Safety End Points in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Clinical and Translational Science, 2021, 14, 184-193. | 1.5 | 3 |
| 15 | Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL. Blood, 2021, 137, 2463-2480. | 0.6 | 35 |
| 16 | Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. Leukemia, 2021, 35, 1166-1175. | 3.3 | 5 |
| 17 | Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosomeâ€“positive relapsed/refractory acute lymphoblastic leukemia. Cancer, 2021, 127, 905-913. | 2.0 | 30 |
| 18 | Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research, 2021, 27, 2742-2754. | 3.2 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Reconstructing the Lineage Histories and Differentiation Trajectories of Individual Cancer Cells in Myeloproliferative Neoplasms. Cell Stem Cell, 2021, 28, 514-523.e9. | 5.2 | 130 |
| 20 | Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science Translational Medicine, 2021, 13, . | 5.8 | 29 |
| 21 | Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021. Haematologica, 2021, 106, 1787-1793. | 1.7 | 5 |
| 22 | Pretreatment clinical and genetic factors predict early postâ€treatment mortality in fit <scp>AML</scp> patients following induction. American Journal of Hematology, 2021, 96, E259-E262. | 2.0 | 1 |
| 23 | KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22. | 0.6 | 90 |
| 24 | The clinical and functional effects of TERT variants in myelodysplastic syndrome. Blood, 2021, 138, 898-911. | 0.6 | 27 |
| 25 | KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502. | 6.3 | 315 |
| 26 | Racial and ethnic enrollment disparities and demographic reporting requirements in acute leukemia clinical trials. Blood Advances, 2021, 5, 4352-4360. | 2.5 | 14 |
| 27 | Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Advances, 2021, 5, 5536-5545. | 2.5 | 24 |
| 28 | Safety and Pharmacokinetics of Calaspargase Pegol in Adults with Newly Diagnosed Philadelphia-Negative ALL: A Phase 2/3 Study. Blood, 2021, 138, 4406-4406. | 0.6 | 1 |
| 29 | Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 1284-1284. | 0.6 | 0 |
| 30 | Antifungal Prophylaxis: Impact on Outcomes of Newly Diagnosed AML Patients Treated with a Hypomethylating Agent and Venetoclax. Blood, 2021, 138, 4126-4126. | 0.6 | 0 |
| 31 | Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study. Blood, 2021, 138, 2565-2565. | 0.6 | 2 |
| 32 | Clinical Characteristics and Outcomes of Patients with Newly Diagnosed De Novo Acute Myeloid Leukemia (AML) during the COVID-19 Pandemic. Blood, 2021, 138, 2291-2291. | 0.6 | 2 |
| 33 | Effective Control of Advance Systemic Mastocytosis with Avapritinib: Mutational Analysis from the Explorer Clinical Study. Blood, 2021, 138, 318-318. | 0.6 | 16 |
| 34 | A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 4440-4440. | 0.6 | 2 |
| 35 | A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 4429-4429. | 0.6 | 1 |
| 36 | Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. Blood, 2021, 138, 372-372. | 0.6 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL in Adults. Blood, 2021, 138, 2305-2305. | 0.6 | 12 |
| 38 | Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine, 2021, 27, 2183-2191. | 15.2 | 78 |
| 39 | Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. Nature Medicine, 2021, 27, 2192-2199. | 15.2 | 79 |
| 40 | Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. Modern Pathology, 2020, 33, 1135-1145. | 2.9 | 12 |
| 41 | Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e122-e133. | 2.2 | 19 |
| 42 | Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to reâ€induction chemotherapy. American Journal of Hematology, 2020, 95, 245-250. | 2.0 | 13 |
| 43 | Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research, 2020, 88, 106283. | 0.4 | 32 |
| 44 | Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden. Blood Cancer Journal, 2020, 10, 81. | 2.8 | 34 |
| 45 | Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S44-S47. | 0.2 | 3 |
| 46 | Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. British Journal of Haematology, 2020, 191, e77-e81. | 1.2 | 3 |
| 47 | Recent Advances in Managing Acute Lymphoblastic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 330-342. | 1.8 | 40 |
| 48 | Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leukemia and Lymphoma, 2020, 61, 2012-2015. | 0.6 | 10 |
| 49 | A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Advances, 2020, 4, 1683-1689. | 2.5 | 43 |
| 50 | The prevention and management of asparaginaseâ€related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH. Journal of Thrombosis and Haemostasis, 2020, 18, 278-284. | 1.9 | 26 |
| 51 | Pioneer Part 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib in Indolent Systemic Mastocytosis. Blood, 2020, 136, 41-42. | 0.6 | 6 |
| 52 | Pure Pathologic Response Is Associated with Improved Overall Survival in Patients with Advanced Systemic Mastocytosis Receiving Avapritinib in the Phase I EXPLORER Study. Blood, 2020, 136, 37-38. | 0.6 | 10 |
| 53 | Maximal Tolerated Dose of the BCL-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction in Previously Untreated Adults with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 40-41. | 0.6 | 10 |
| 54 | Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1385-1415. | 2.3 | 147 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. Journal of Clinical Pathology, 2019, 72, 93-96. | 1.0 | 4 |
| 56 | Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist, 2019, 24, 247-254. | 1.9 | 55 |
| 57 | Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood, 2019, 134, 867-879. | 0.6 | 55 |
| 58 | Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. Leukemia Research, 2019, 85, 106197. | 0.4 | 16 |
| 59 | Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer, 2019, 125, 3845-3852. | 2.0 | 10 |
| 60 | Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123. | 2.0 | 77 |
| 61 | Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 1720-1729. | 2.0 | 53 |
| 62 | Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and longâ€term survival followâ€up from the randomized, phase 3 INOâ€VATE study. Cancer, 2019, 125, 2474-2487. | 2.0 | 210 |
| 63 | Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia, 2019, 33, 2393-2402. | 3.3 | 44 |
| 64 | Tâ€cell acute lymphoblastic leukemia: Current approach and future directions. Advances in Cell and Gene Therapy, 2019, 2, e70. | 0.6 | 4 |
| 65 | Rate of differentiation syndrome in patients based on timing of initial all-trans retinoic acid administration. Leukemia Research Reports, 2019, 12, 100189. | 0.2 | 2 |
| 66 | Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. New England Journal of Medicine, 2019, 381, 2315-2326. | 13.9 | 257 |
| 67 | Colonic Wall Thickening as the First Indicator of Relapse of Acute Lymphoblastic Leukemia. ACG Case Reports Journal, 2019, 6, e00207. | 0.2 | 0 |
| 68 | Single 6-mg dose of rasburicase: The experience in a large academic medical center. Journal of Oncology Pharmacy Practice, 2019, 25, 1349-1356. | 0.5 | 6 |
| 69 | Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin. American Journal of Hematology, 2019, 94, 408-416. | 2.0 | 11 |
| 70 | Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTcâ€concentration modelling. British Journal of Clinical Pharmacology, 2019, 85, 590-600. | 1.1 | 12 |
| 71 | Phase I Trial of Escalating Doses of the Bcl-2 Inhibitor Venetoclax in Combination with Daunorubicin/Cytarabine Induction and High Dose Cytarabine Consolidation in Previously Untreated Adults with Acute Myeloid Leukemia ( AML). Blood, 2019, 134, 3908-3908. | 0.6 | 7 |
| 72 | Pioneer: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy. Blood, 2019, 134, 2950-2950. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | How to treat chronic myeloid leukemia (CML) in older adults. Journal of Geriatric Oncology, 2018, 9, 291-295. | 0.5 | 6 |
| 74 | Exploiting an Asp-Glu â€œswitchâ€•in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine, 2018, 10, . | 5.8 | 69 |
| 75 | Flow cytometric minimal residual disease assessment of peripheral blood in acute lymphoblastic leukaemia patients has potential for early detection of relapsed extramedullary disease. Journal of Clinical Pathology, 2018, 71, 653-658. | 1.0 | 9 |
| 76 | A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected. Oncology and Therapy, 2018, 6, 9-20. | 1.0 | 19 |
| 77 | Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, . | 5.8 | 299 |
| 78 | Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia. JAMA Oncology, 2018, 4, 725. | 3.4 | 111 |
| 79 | Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INOâ€VATE. Cancer, 2018, 124, 1722-1732. | 2.0 | 43 |
| 80 | The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. Journal of Thrombosis and Thrombolysis, 2018, 45, 306-314. | 1.0 | 31 |
| 81 | High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood, 2018, 131, 2816-2825. | 0.6 | 64 |
| 82 | Ponatinib efficacy and safety in Philadelphia chromosomeâ€“positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018, 132, 393-404. | 0.6 | 392 |
| 83 | A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood, 2018, 131, 387-396. | 0.6 | 131 |
| 84 | A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, 254-261. | 2.0 | 12 |
| 85 | Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. Journal of Hematology and Oncology, 2018, 11, 143. | 6.9 | 52 |
| 86 | New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2018, 36, 3504-3519. | 0.8 | 67 |
| 87 | Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. British Journal of Cancer, 2018, 118, 1425-1433. | 2.9 | 72 |
| 88 | A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood, 2018, 132, 1125-1133. | 0.6 | 60 |
| 89 | Treatment of young adults with Philadelphiaâ€negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyperâ€CVAD vs. pediatricâ€inspired regimens. American Journal of Hematology, 2018, 93, 1254-1266. | 2.0 | 29 |
| 90 | Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema. Journal of Neuropathology and Experimental Neurology, 2018, 77, 877-882. | 0.9 | 95 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Glasdegib in combination with cytarabine and daunorubicin in patients with AML or highâ€risk MDS: Phase 2 study results. American Journal of Hematology, 2018, 93, 1301-1310. | 2.0 | 98 |
| 92 | Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM): Analyses of Patient Reported Outcomes (PROs) from the Phase 1 (EXPLORER) Study Using the (AdvSM) Symptom Assessment Form (AdvSM-SAF), a New PRO Questionnaire for (AdvSM). Blood, 2018, 132, 351-351. | 0.6 | 15 |
| 93 | Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML). Blood, 2018, 132, 3895-3895. | 0.6 | 0 |
| 94 | Tailored Approaches to Induction Therapy for Acute Promyelocytic Leukemia. Journal of Clinical Oncology, 2017, 35, 583-586. | 0.8 | 4 |
| 95 | Selfâ€reported sleep disturbance and survival in myelodysplastic syndromes. British Journal of Haematology, 2017, 177, 562-566. | 1.2 | 16 |
| 96 | Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. Histopathology, 2017, 71, 112-124. | 1.6 | 10 |
| 97 | The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine, 2017, 23, 301-313. | 15.2 | 79 |
| 98 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood, 2017, 130, 722-731. | 0.6 | 1,173 |
| 99 | Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Therapeutic Advances in Hematology, 2017, 8, 3-12. | 1.1 | 5 |
| 100 | Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Expert Review of Hematology, 2017, 10, 1033-1045. | 1.0 | 14 |
| 101 | Current challenges and opportunities in treating adult patients with Philadelphiaâ€negative acute lymphoblastic leukaemia. British Journal of Haematology, 2017, 179, 705-723. | 1.2 | 18 |
| 102 | A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Medicine, 2017, 9, . | 5.8 | 157 |
| 103 | NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102. | 2.3 | 67 |
| 104 | Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology,the, 2017, 4, e387-e398. | 2.2 | 158 |
| 105 | Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. Current Hematologic Malignancy Reports, 2017, 12, 370-379. | 1.2 | 15 |
| 106 | Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Advances, 2017, 1, 1167-1180. | 2.5 | 103 |
| 107 | A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances, 2017, 1, 331-340. | 2.5 | 57 |
| 108 | Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. Blood Advances, 2017, 1, 1786-1789. | 2.5 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Neutrophil FcÎ³RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. Journal of Clinical Investigation, 2017, 127, 3810-3826. | 3.9 | 48 |
| 110 | GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. Blood, 2017, 130, 894-894. | 0.6 | 9 |
| 111 | QoL of pediatric-inspired compared to hyper-CVAD regimens for newly diagnosed AYA patients with Ph-ALL: A modeling analysis.. Journal of Clinical Oncology, 2017, 35, e22002-e22002. | 0.8 | 1 |
| 112 | Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e302-e312. | 1.8 | 8 |
| 113 | Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer, 2016, 122, 2379-2388. | 2.0 | 23 |
| 114 | Pediatricâ€inspired therapy compared to allografting for <scp>P</scp>hiladelphia chromosomeâ€negative adult ALL in first complete remission. American Journal of Hematology, 2016, 91, 322-329. | 2.0 | 72 |
| 115 | Allogeneic transplantation is not superior to chemotherapy in most patients over 40Âyears of age with Philadelphiaâ€negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799. | 2.0 | 14 |
| 116 | NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1505-1512. | 2.3 | 57 |
| 117 | Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematology,the, 2016, 3, e276-e283. | 2.2 | 19 |
| 118 | The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell, 2016, 29, 574-586. | 7.7 | 227 |
| 119 | Haematopoietic cell transplantation with and without sorafenib maintenance for patients with <scp>FLT</scp>3â€<scp>ITD</scp> acute myeloid leukaemia in first complete remission. British Journal of Haematology, 2016, 175, 496-504. | 1.2 | 162 |
| 120 | Targeting MTHFD2 in acute myeloid leukemia. Journal of Experimental Medicine, 2016, 213, 1285-1306. | 4.2 | 118 |
| 121 | Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. New England Journal of Medicine, 2016, 375, 740-753. | 13.9 | 1,047 |
| 122 | Functionally identifiable apoptosis-insensitive subpopulations determine chemoresistance in acute myeloid leukemia. Journal of Clinical Investigation, 2016, 126, 3827-3836. | 3.9 | 40 |
| 123 | Preliminary Safety and Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM). Blood, 2016, 128, 477-477. | 0.6 | 12 |
| 124 | Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget, 2016, 7, 20152-20165. | 0.8 | 22 |
| 125 | A Distributed International Patient Data Registry for Hairy Cell Leukemia. Blood, 2016, 128, 5986-5986. | 0.6 | 0 |
| 126 | RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability. Cell Reports, 2015, 13, 2345-2352. | 2.9 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2015, 2015, 400-405. | 0.9 | 16 |
| 128 | Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125, 1367-1376. | 0.6 | 747 |
| 129 | Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279. | 2.3 | 116 |
| 130 | Health care utilization and endâ€ofâ€life care for older patients with acute myeloid leukemia. Cancer, 2015, 121, 2840-2848. | 2.0 | 113 |
| 131 | Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Modern Pathology, 2015, 28, 965-976. | 2.9 | 31 |
| 132 | Myeloid neoplasm demonstrating a STAT5B-RARA rearrangement and genetic alterations associated with all-trans retinoic acid resistance identified by a custom next-generation sequencing assay. Journal of Physical Education and Sports Management, 2015, 1, a000307. | 0.5 | 13 |
| 133 | Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. Journal of Geriatric Oncology, 2015, 6, 288-298. | 0.5 | 29 |
| 134 | Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes. Leukemia Research, 2015, 39, 204-210. | 0.4 | 13 |
| 135 | Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia. Open Forum Infectious Diseases, 2015, 2, ofv096. | 0.4 | 13 |
| 136 | Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 28, 29-41. | 7.7 | 95 |
| 137 | Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the Î³-secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. Journal of Physical Education and Sports Management, 2015, 1, a000539. | 0.5 | 47 |
| 138 | A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma. Blood, 2015, 126, 1328-1328. | 0.6 | 43 |
| 139 | ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. Blood, 2015, 126, 138-138. | 0.6 | 22 |
| 140 | DC/Aml Fusion Cell Vaccination Administered to AML Patients Who Achieve a Complete Remission Potently Expands Leukemia Reactive T Cells and Is Associated with Durable Remissions. Blood, 2015, 126, 2549-2549. | 0.6 | 5 |
| 141 | Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. Blood, 2015, 126, 2861-2861. | 0.6 | 7 |
| 142 | Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial. Blood, 2015, 126, 323-323. | 0.6 | 57 |
| 143 | A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood, 2015, 126, 324-324. | 0.6 | 26 |
| 144 | Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial. Blood, 2015, 126, 4025-4025. | 0.6 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | SGN-CD33A Plus Hypomethylating Agents: A Novel, Well-Tolerated Regimen with High Remission Rate in Frontline Unfit AML. Blood, 2015, 126, 454-454. | 0.6 | 29 |
| 146 | A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial. Blood, 2015, 126, 80-80. | 0.6 | 38 |
| 147 | A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. Blood, 2015, 126, 2553-2553. | 0.6 | 0 |
| 148 | Targeting MTHFD2 in Acute Myeloid Leukemia. Blood, 2015, 126, 443-443. | 0.6 | 2 |
| 149 | Identification of CKMT1B As a New Target in EVI1-Positive AML. Blood, 2015, 126, 3674-3674. | 0.6 | 0 |
| 150 | Health Care Utilization and End of Life Care for Older Patients with Acute Myeloid Leukemia Receiving Supportive Care Alone. Blood, 2015, 126, 2126-2126. | 0.6 | 0 |
| 151 | Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study. Blood, 2015, 126, 5142-5142. | 0.6 | 0 |
| 152 | A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2015, 126, 2550-2550. | 0.6 | 0 |
| 153 | Identification of a First in Class GSK3-Alpha Selective Inhibitor As a New Differentiation Therapy for AML. Blood, 2015, 126, 870-870. | 0.6 | 0 |
| 154 | Nuclear Export Inhibitor KPT-8602 Is Highly Active Against Leukemic Blasts and Leukemia-Initiating Cells in Patient-Derived Xenograft Models of AML. Blood, 2015, 126, 326-326. | 0.6 | 0 |
| 155 | Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. Blood, 2015, 126, 1304-1304. | 0.6 | 0 |
| 156 | Potentially Avoidable Hospitalizations in Older Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3310-3310. | 0.6 | 0 |
| 157 | Impact of Timely Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor After 12-Month Complete Cytogenetic Response Failure: A Chart Review Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 245-251. | 0.2 | 6 |
| 158 | Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199. Cancer Discovery, 2014, 4, 1074-1087. | 7.7 | 201 |
| 159 | SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 226-242. | 7.7 | 126 |
| 160 | A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leukemia Research, 2014, 38, 430-434. | 0.4 | 23 |
| 161 | The Pim-1 Protein Kinase Is an Important Regulator of MET Receptor Tyrosine Kinase Levels and Signaling. Molecular and Cellular Biology, 2014, 34, 2517-2532. | 1.1 | 48 |
| 162 | AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood, 2014, 123, 905-913. | 0.6 | 205 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | A Phase II Study of Weekly Inotuzumab Ozogamicin (InO) in Adult Patients with CD22-Positive Acute Lymphoblastic Leukemia (ALL) in Second or Later Salvage. Blood, 2014, 124, 2255-2255. | 0.6 | 18 |
| 164 | The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial. Blood, 2014, 124, 968-968. | 0.6 | 34 |
| 165 | Switching drugs midstream for patients with chronic myeloid leukemia. Clinical Advances in Hematology and Oncology, 2014, 12, 466-8. | 0.3 | 0 |
| 166 | Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia. Cancer, 2013, 119, 90-98. | 2.0 | 104 |
| 167 | Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leukemia Research, 2013, 37, 1016-1020. | 0.4 | 26 |
| 168 | Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. Leukemia Research, 2013, 37, 747-751. | 0.4 | 16 |
| 169 | Phase <scp>II</scp> trial of panobinostat, an oral panâ€deacetylase inhibitor in patients with primary myelofibrosis, postâ€“essential thrombocythaemia, and postâ€“polycythaemia vera myelofibrosis. British Journal of Haematology, 2013, 162, 326-335. | 1.2 | 61 |
| 170 | Refrigeration is not necessary for measurement of uric acid in patients treated with rasburicase. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1053-7. | 1.4 | 6 |
| 171 | International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood, 2013, 121, 2393-2401. | 0.6 | 122 |
| 172 | A First-In-Human Phase 1 Study Of The Antibody-Drug Conjugate SGN-CD19A In Relapsed Or Refractory B-Lineage Acute Leukemia and Highly Aggressive Lymphoma. Blood, 2013, 122, 1437-1437. | 0.6 | 12 |
| 173 | MLN4924, a Novel Investigational Inhibitor Of NEDD8-Activating Enzyme (NAE), In Adult Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS): Results From Multiple Dosing Schedules In a Phase 1 Study. Blood, 2013, 122, 1443-1443. | 0.6 | 4 |
| 174 | Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs). Blood, 2013, 122, 1496-1496. | 0.6 | 4 |
| 175 | BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia. Blood, 2013, 122, 238-238. | 0.6 | 2 |
| 176 | Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL). Blood, 2013, 122, 3906-3906. | 0.6 | 9 |
| 177 | Flow Cytometric Evaluation Of Minimal Residual Disease In Adult Acute Lymphoblastic Leukemia Using a Simplified, Single-Tube Approach. Blood, 2013, 122, 1378-1378. | 0.6 | 0 |
| 178 | HSP90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase. Blood, 2013, 122, 2528-2528. | 0.6 | 0 |
| 179 | Targeting Oncogenic Interleukein-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2535-2535. | 0.6 | 0 |
| 180 | The Safety and Adherence To Prophylactic Anticoagulation During Induction Chemotherapy In Adults With Acute Lymphoblastic Leukemia. Blood, 2013, 122, 3867-3867. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Aberrant Splicing In Patients With AML Is Associated With Over- Expression Of Specific Splicing Factors. Blood, 2013, 122, 3749-3749. | 0.6 | 3 |
| 182 | Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML. Cell, 2012, 151, 344-355. | 13.5 | 294 |
| 183 | The intersection of genetic and chemical genomic screens identifies GSK-3Î± as a target in human acute myeloid leukemia. Journal of Clinical Investigation, 2012, 122, 935-947. | 3.9 | 96 |
| 184 | A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502. Blood, 2012, 120, 230-230. | 0.6 | 14 |
| 185 | Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial. Blood, 2012, 120, 3747-3747. | 0.6 | 6 |
| 186 | Efficacy and Safety of Ponatinib According to Prior Approved Tyrosine Kinase Inhibitor (TKI) Therapy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CP-CML): Results From the PACE Trial. Blood, 2012, 120, 3749-3749. | 0.6 | 2 |
| 187 | Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial. Blood, 2012, 120, 3763-3763. | 0.6 | 5 |
| 188 | Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 0 0 rgBT /Overlock 1 | 0.6 | |
| 189 | Benefits of Early Switching From Imatinib to a Second-Generation Tyrosine Kinase Inhibitor Following 12 Month Complete Cytogenetic Response Failure: A Chart Review Analysis.. Blood, 2012, 120, 2792-2792. | 0.6 | 0 |
| 190 | Geriatric Assessment Variables Add Prognostic Value to the International Prognostic Scoring System. Blood, 2012, 120, 4933-4933. | 0.6 | 0 |
| 191 | Prospective Cohort Study of Geriatric Assessment in Older Patients with Acute Myeloid Leukemia. Blood, 2012, 120, 4285-4285. | 0.6 | 15 |
| 192 | Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. Science, 2011, 334, 1129-1133. | 6.0 | 502 |
| 193 | Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia and Lymphoma, 2011, 52, 2237-2253. | 0.6 | 198 |
| 194 | Preface. Hematology/Oncology Clinics of North America, 2011, 25, ix-x. | 0.9 | 0 |
| 195 | The frequency and management of asparaginaseâ€related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Danaâ€Farber Cancer Institute consortium protocols. British Journal of Haematology, 2011, 152, 452-459. | 1.2 | 216 |
| 196 | Measuring Mitochondrial Apoptotic Priming by BH3 Profiling Predicts Induction Outcome for Acute Myeloid Leukemia Patients. Blood, 2011, 118, 239-239. | 0.6 | 0 |
| 197 | Mitochondrial Apoptotic Priming Measured by BH3 Profiling Regulates Clinical Response to Chemotherapy in Myeloma and Acute Lymphoblastic Leukemia and Explains Therapeutic Index. Blood, 2011, 118, 1442-1442. | 0.6 | 0 |
| 198 | Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3. Journal of Clinical Oncology, 2010, 28, 4339-4345. | 0.8 | 442 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leukemia and Lymphoma, 2010, 51, 363-375. | 0.6 | 13 |
| 200 | KIT Inhibitor Midostaurin Exhibits a High Rate of Clinically Meaningful and Durable Responses in Advanced Systemic Mastocytosis: Report of a Fully Accrued Phase II Trial. Blood, 2010, 116, 316-316. | 0.6 | 33 |
| 201 | The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study. Blood, 2010, 116, 658-658. | 0.6 | 7 |
| 202 | Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3Î± (GSK-3Î±) as a Modulator of Differentiation In Acute Myeloid Leukemia. Blood, 2010, 116, 1000-1000. | 0.6 | 0 |
| 203 | Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. JAMA - Journal of the American Medical Association, 2009, 301, 2349. | 3.8 | 758 |
| 204 | Nelarabine for the Treatment of Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma. Hematology/Oncology Clinics of North America, 2009, 23, 1121-1135. | 0.9 | 35 |
| 205 | Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 984-1023. | 2.3 | 151 |
| 206 | Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood, 2009, 114, 4027-4033. | 0.6 | 52 |
| 207 | Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia.. Blood, 2009, 114, 2209-2209. | 0.6 | 22 |
| 208 | Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.. Blood, 2009, 114, 2898-2898. | 0.6 | 7 |
| 209 | The Frequency and Management of Asparaginase-Related Thrombosis in Pediatric and Adult Patients with Acute Lymphoblastic Leukemia Treated On the Dana-Farber Cancer Institute (DFCI) Consortium Protocols.. Blood, 2009, 114, 3073-3073. | 0.6 | 1 |
| 210 | A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 587-587. | 0.6 | 2 |
| 211 | Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011. | 0.6 | 1 |
| 212 | Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies.. Blood, 2008, 112, 958-958. | 0.6 | 32 |
| 213 | Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. Journal of Clinical Oncology, 2007, 25, 813-819. | 0.8 | 171 |
| 214 | Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood, 2007, 109, 5136-5142. | 0.6 | 287 |
| 215 | Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project. Leukemia Research, 2007, 31, 599-604. | 0.4 | 164 |
| 216 | Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4496-4496. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2007, 110, 587-587. | 0.6 | 47 |
| 218 | JAK2 V617F in Patients with Idiopathic Thromboses in Common Locations.. Blood, 2007, 110, 1634-1634. | 0.6 | 0 |
| 219 | Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood, 2006, 108, 3477-3483. | 0.6 | 194 |
| 220 | Phase 1/2 Study of Tandutinib (MLN518) Plus Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML).. Blood, 2006, 108, 158-158. | 0.6 | 12 |
| 221 | A Multicenter Phase II Study Using a Dose Intensified Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia.. Blood, 2006, 108, 1858-1858. | 0.6 | 4 |
| 222 | Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. Blood, 2006, 108, 259-259. | 0.6 | 1 |
| 223 | A Double Blind Placebo-Controlled Randomized Phase III Study of High Dose Continuous Infusion Cytosine Arabinoside (araC) with or without CloretazineÂ® in Patients with First Relapse of Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 1970-1970. | 0.6 | 0 |
| 224 | Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood, 2005, 105, 54-60. | 0.6 | 632 |
| 225 | The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2005, 2005, 123-130. | 0.9 | 50 |
| 226 | Leukemia Derived Dendritic Cells (LDCs) Are Functionally Deficient and Inferior to DC/Leukemia Fusion Cells as a Tumor Vaccine for AML.. Blood, 2005, 106, 2788-2788. | 0.6 | 0 |
| 227 | Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation. Clinical Cancer Research, 2004, 10, 5065-5071. | 3.2 | 72 |
| 228 | High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185. | 0.6 | 0 |
| 229 | Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300. | 0.6 | 2 |
| 230 | A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome. New England Journal of Medicine, 2003, 348, 1201-1214. | 13.9 | 1,655 |
| 231 | Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 2003, 102, 1578-1582. | 0.6 | 299 |
| 232 | Differentiation and reversal of malignant changes in colon cancer through PPARÎ³. Nature Medicine, 1998, 4, 1046-1052. | 15.2 | 933 |